Hansoh Pharmaceutical Group Company Limited (BKK:HANSOH19)

Market Cap	885.57B -2.8%
Revenue (ttm)	77.84B +20.5%
Net Income	32.70B +39.7%
EPS	5.42 +37.9%
Shares Out	n/a
PE Ratio	27.08
Forward PE	26.91
Dividend	0.08 (1.37%)
Ex-Dividend Date	Sep 22, 2026

Volume	2,518
Open	5.80
Previous Close	6.10
Day's Range	5.80 - 5.90
52-Week Range	4.76 - 6.70
Beta	0.56
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About BKK:HANSOH19

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 9,643
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: HANSOH19

Financial Performance

In 2025, BKK:HANSOH19's revenue was 15.03 billion, an increase of 22.57% compared to the previous year's 12.26 billion. Earnings were 5.56 billion, an increase of 27.07%.

Financial numbers in CNY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Data Sources Report a data error